Dr. Apolo on Study of Cabozantinib Plus Nivolumab and Ipilimumab in Urothelial Carcinoma

Andrea B. Apolo, MD
Published: Thursday, Feb 16, 2017



Andrea B. Apolo, MD, chief of bladder cancer section, National Cancer Institute, discusses a phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors.

In this study, the combinations of cabozantinib/nivolumab and cabozantinib/nivolumab/ipilimumab were evaluated for safety and clinical activity. Both combinations were well tolerated and responses were seen at all dose levels, with the recommended doses at 40 mg cabozantinib/3 mg nivolumab and 40 mg cabozantinib/3 mg nivolumab/1 mg ipilimumab.

In addition to responses in patients with mUC, rare tumors such as basaloid squamous cell carcinoma, urachal, and penile cancer also showed significant responses.
 

<<< View more from the 2017 Genitourinary Cancers Symposium



Andrea B. Apolo, MD, chief of bladder cancer section, National Cancer Institute, discusses a phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors.

In this study, the combinations of cabozantinib/nivolumab and cabozantinib/nivolumab/ipilimumab were evaluated for safety and clinical activity. Both combinations were well tolerated and responses were seen at all dose levels, with the recommended doses at 40 mg cabozantinib/3 mg nivolumab and 40 mg cabozantinib/3 mg nivolumab/1 mg ipilimumab.

In addition to responses in patients with mUC, rare tumors such as basaloid squamous cell carcinoma, urachal, and penile cancer also showed significant responses.
 

<<< View more from the 2017 Genitourinary Cancers Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x